UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Nature communications, 2020-01, Vol.11 (1), p.74-16, Article 74

2020

Volltextzugriff (PDF)

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

Cancer chemotherapy and pharmacology, 2019-04, Vol.83 (4), p.659-671

2019

Volltextzugriff (PDF)

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Molecular cancer research, 2019-01, Vol.17 (1), p.212-224

2019

Volltextzugriff (PDF)

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

BMC cancer, 2019-04, Vol.19 (1), p.301-301, Article 301

2019

Volltextzugriff (PDF)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

NPJ precision oncology, 2023-10, Vol.7 (1), p.107-107, Article 107

2023

Volltextzugriff (PDF)

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

Molecular cancer therapeutics, 2020-06, Vol.19 (6), p.1320-1327

2020

Volltextzugriff (PDF)

Loss of an EGFR -amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR -mutated NSCLC cells

Lung cancer (Amsterdam, Netherlands), 2014-01, Vol.83 (1), p.44-50

2014

Volltextzugriff (PDF)

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

Clinical & experimental metastasis, 2011-10, Vol.28 (7), p.649-659

2011

Volltextzugriff (PDF)

Bevacizumab improves the delivery and efficacy of paclitaxel

Anti-cancer drugs, 2010-08, Vol.21 (7), p.687-694

2010

Volltextzugriff (PDF)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

Anti-cancer drugs, 2022-02, Vol.33 (2), p.124-131

2022

Volltextzugriff (PDF)

Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells

Cancer biology & therapy, 2020-09, Vol.21 (9), p.863-870

2020

Volltextzugriff (PDF)

Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models

Clinical cancer research, 2011-08, Vol.17 (15), p.5060-5070

2011

Volltextzugriff (PDF)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

International journal of oncology, 2017-08, Vol.51 (2), p.425-434

2017

Volltextzugriff (PDF)

Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus

Journal of immunological methods, 2007-04, Vol.322 (1), p.104-117

2007

Volltextzugriff (PDF)

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer

Molecular oncology, 2024-10

2024

Volltextzugriff (PDF)

Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification

International journal of cancer, 2016-02, Vol.138 (4), p.1024-1032

2016

Volltextzugriff (PDF)

Abstract 1271: ABCC11 is involved in resistance to alectinib

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1271-1271

2019

Volltextzugriff (PDF)

Abstract 72: YAP1 mediates initial survival of alectinib therapy in ALK-rearranged lung cancer via pro-apoptotic protein regulation

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.72-72

2019

Volltextzugriff (PDF)

Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.256-256

2018

Volltextzugriff (PDF)

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells

Biochemical and biophysical research communications, 2009-01, Vol.378 (2), p.279-284

2009

Volltextzugriff (PDF)

Abstract 1830: A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1830-1830

2018

Volltextzugriff (PDF)

Bevacizumab improves the delivery and efficacy of paclitaxel

Anti-cancer drugs, 2010-08, Vol.21 (7), p.687-694

2010

Volltextzugriff (PDF)

Melting curve analysis for mutations of EGFR and KRAS

Anticancer research, 2014-02, Vol.34 (2), p.613-621

2014

Volltextzugriff (PDF)

Effect of loss of a chromosome 7 containing multiple copies of EGFR gene on acquired resistance to EGFR-TKIs in EGFR mutated NSCLC

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18091-e18091

2012

Volltextzugriff (PDF)

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

BioMed research international, 2017-01, Vol.2017 (2017), p.1-7

2017

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(19)
Oncology
(17)
Animals
(14)
Humans
(14)
Mice
(13)
Cell Line, Tumor
(11)
Xenograft Model Antitumor Assays
(9)
Lung Cancer
(8)
Male
(8)
Tumors
(8)
Mutation
(7)
Kinases
(6)
Mice, Inbred Balb C
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Carcinoma, Non-Small-Cell Lung - Pathology
(5)
Erlotinib
(5)
Female
(5)
Lung Neoplasms - Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

Loss of an EGFR -amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR -mutated NSCLC cells

Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

Bevacizumab improves the delivery and efficacy of paclitaxel

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells

Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer

Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification

Abstract 1271: ABCC11 is involved in resistance to alectinib

Abstract 72: YAP1 mediates initial survival of alectinib therapy in ALK-rearranged lung cancer via pro-apoptotic protein regulation

Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells

Abstract 1830: A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer

Bevacizumab improves the delivery and efficacy of paclitaxel

Melting curve analysis for mutations of EGFR and KRAS

Effect of loss of a chromosome 7 containing multiple copies of EGFR gene on acquired resistance to EGFR-TKIs in EGFR mutated NSCLC

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

Suchergebnisse filtern